Praxis Precision Medicines (PRAX) Expected to Announce Earnings on Tuesday

Praxis Precision Medicines (NASDAQ:PRAX) is expected to issue its quarterly earnings data before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($2.76) per share and revenue of $0.36 million for the quarter.

Praxis Precision Medicines Stock Down 10.4 %

Shares of Praxis Precision Medicines stock opened at $66.71 on Tuesday. Praxis Precision Medicines has a 12-month low of $33.01 and a 12-month high of $91.83. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -6.48 and a beta of 2.65. The firm’s 50-day moving average price is $77.30 and its two-hundred day moving average price is $69.56.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on PRAX. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Praxis Precision Medicines in a research note on Tuesday, February 11th. They issued a “buy” rating and a $111.00 price objective on the stock. Truist Financial lifted their price target on Praxis Precision Medicines from $150.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, January 21st. Needham & Company LLC restated a “buy” rating and set a $150.00 price objective on shares of Praxis Precision Medicines in a research report on Monday, February 10th. Oppenheimer lifted their target price on Praxis Precision Medicines from $143.00 to $163.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $120.00 target price on shares of Praxis Precision Medicines in a report on Thursday, December 12th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Praxis Precision Medicines has an average rating of “Moderate Buy” and a consensus target price of $145.20.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.